Genesis Electrical Impedance Tomography (EIT): A Preliminary Study

Overview

The purpose of this study is to evaluate the Genesis Electrical Impedance Tomography (EIT) imaging system for use in pediatric respiratory disease populations including neuromuscular and bronchopulmonary dysplasia, as well as in age and height matched controls. The EIT does not use radiation, and is read through electrodes.

Full Title of Study: “The Associations Between EIT and Clinical Measures During Standard of Care Procedures in Patients With Respiratory Disease: A Preliminary Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 30, 2024

Detailed Description

The purpose of this study is to evaluate EIT for use in pediatric respiratory disease populations including neuromuscular and bronchopulmonary dysplasia, as well as in age and height matched controls. Researchers will use EIT to determine changes in regional ventilation with pulmonary interventions including airway clearance and invasive and noninvasive ventilation in a pediatric respiratory disease population.

Arms, Groups and Cohorts

  • Premature Infants
    • Premature infants >1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
  • Chronic Respiratory Disease
    • Participants ages >1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
  • Neuromuscular Disease
    • Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
  • Healthy Controls
    • Age and height matched healthy controls
  • V/Q Scan validation
    • Adults or children who are having or have recently had a V/Q scan
  • Premature Infants (Longitudinal Cohort)
    • Premature infants ages 2 weeks to 1 year with diagnosed or suspected bronchopulmonary dysplasia
  • Pulmonary Vein/Artery Stenosis
    • Children age 2 months to 18 years, who will be undergoing cardiac catheterization for pulmonary vein stenosis, pulmonary hypertension and/or pulmonary artery stenosis

Clinical Trial Outcome Measures

Primary Measures

  • EIT imaging maps that provide regional information regarding ventilation and perfusion of the lung.
    • Time Frame: 24 months
    • These images will be analyzed both visually for qualitative abnormalities and through quantitative pixel analysis that can provide information regarding lung volume, blood volume, and changes in either based on respiratory cycle, cardiac cycle, or intervention. Areas of low ventilation (atelectasis and consolidation) will be identified.

Secondary Measures

  • Regional conductivity changes due to ventilation
    • Time Frame: 24 months
    • Describe regional ventilation in pediatric respiratory disease populations including neuromuscular weakness, skeletal/chest wall disorders, and chronic airway and parenchymal lung disease including bronchopulmonary dysplasia. This is a qualitative aim and will summarize EIT images pictorially. Pixel densities will be evaluated for normality and summarized as mean (SD) or median (interquartile range). EIT images will be qualitatively compared between cases and controls.
  • Waveform for a mesh element
    • Time Frame: 24 months
    • Time-series waveform indicated by time in seconds compared to Recon signal (au).
  • Regional conductivity changes due to perfusion
    • Time Frame: 24 months
    • This is a qualitative and quantitative aim. Results will qualitatively compare EIT images with CXR and CT scan images when available. Images will be displayed side by side and interpreted by both the clinician and the EIT study staff. Various summary measures of EIT outcomes will be calculated including pixel heterogeneity, summary changes over tidal breath and variation between tidal peaks. Pearson and Spearman correlation will be calculated between summary EIT outcomes and continuous primary clinical values. Linear and logistic regression will be used to estimate associations (with 95% CI) between EIT measures and clinical outcomes. Summary data will be presented in tables and figures using basic descriptive statistics stratified by study group.
  • Regional pulsatile perfusion imaging at the end of systole
    • Time Frame: 5 minutes
  • Power waveform (computed as the inner product of measured voltages and applied currents)
    • Time Frame: 24 months

Participating in This Clinical Trial

Inclusion Criteria

  • 2 weeks old – 40 years old – Premature infants with current age >2 weeks with a confirmed diagnosis of BPD based on NIH criteria – Or Chronic respiratory disease due to underlying neuromuscular disease – Or confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of DMD or other diagnoses associated with mild cardiomyopathy. – have had a VQ scan – will be undergoing cardiac catherization for for pulmonary vein stenosis, pulmonary hypertension and/or pulmonary artery stenosis – Or healthy controls Exclusion Criteria:

  • <2 weeks of age – Congenital diaphragmatic hernia – Severe congenital heart disease – Significant genetic abnoralities – Anything that interferes with lead placement on the chest wall – Unwilling/refusal to sign consent – Pregnant or lactating – Pacemaker of other surgical implant and spinal implant (causes noise in the data) – Moderate to severe cardiomyopathy – Patients with temporary cognitive disability due to illness

Gender Eligibility: All

Minimum Age: 14 Days

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Colorado, Denver
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Emily DeBoer, MD, 720-777-4953, emily.deboer@childrenscolorado.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.